[PFE returns Rituxan/Herceptin rights to Celltrion; PFE’s internal (i.e. non-HSP) programs for these FoBs are more advanced than the Celltrion programs originally partnered with HSP.]
Items are shown in reverse chronological order. This table does not purport to be exhaustive.